Premium
Delayed oral toxicity from long‐term vemurafenib therapy
Author(s) -
LloydLavery A.,
Hodgson T.,
Coupe N.,
Bond S.,
Shah K.,
Espinosa O.,
Payne M.J.,
Middleton M.R.,
Matin R.N.
Publication year - 2016
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.14457
Subject(s) - medicine , vemurafenib , toxicity , asymptomatic , lesion , basal cell , dermatology , oncology , gastroenterology , surgery , cancer , metastatic melanoma
We read with interest the article by Vigarios et al.1 describing eight patients treated with a variety of BRAF inhibitors who developed asymptomatic hyperkeratotic oral mucosal lesions. These were frequently multifocal and presented following a mean onset of three months of treatment with a BRAF inhibitor. In one patient, one such lesion rapidly developed into oral squamous cell carcinoma requiring excision. We would like to highlight delayed oral toxicity in a long-term responder to a BRAF inhibitor.